• In late June 2026, The Clorox Company (NYSE: CLX) was added to both the Russell 2500 Index and the Russell 2500 Value Benchmark, broadening its presence in key US equity indices.
• This index inclusion, alongside renewed interest from institutional investors such as Palm Valley Capital Management following prior operational and cyber-related disruptions, highlights how sentiment and portfolio positioning are evolving around Clorox.
• Next, we’ll examine how Clorox’s fresh Russell index inclusion may influence its existing investment narrative around ERP, innovation, and competition.

Uncover the next big thing with 20 elite penny stocks that balance risk and reward.

Clorox Investment Narrative Recap

To own Clorox, you need to believe its core brands and ongoing ERP and innovation efforts can offset softer demand, rising price competition, and cost pressures. The fresh Russell 2500 and Russell 2500 Value inclusions may bring some added liquidity and institutional attention, but they do not materially change the near term focus on ERP execution as a key catalyst or on consumer trade down and private label competition as the central risk.

The most relevant recent update here is Clorox’s April 2026 guidance cut, which framed expectations for net sales to fall about 6% and EPS to decline 24% to 27% for FY 2026. Against that backdrop, the Russell index additions and Palm Valley Capital’s new position simply sit alongside an investment story still anchored in ERP benefits, cost productivity, and whether innovation can re accelerate organic growth.

Yet beneath the surface, investors should also be aware of how consumer trade down and private label pressure could...

Clorox's narrative projects $7.9 billion revenue and $886.0 million earnings by 2029.

Uncover how Clorox's forecasts yield a $105.29 fair value, a 9% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were expecting Clorox to reach about US$8.3 billion in revenue and US$1.0 billion in earnings, which is much rosier than consensus, so it is worth asking how that view might change now that index inclusion and evolving concerns about trade down behavior are both in focus.

Explore 4 other fair value estimates on Clorox - why the stock might be worth as much as 71% more than the current price!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Clorox research is our analysis highlighting 4 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Clorox research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Clorox's overall financial health at a glance.

No Opportunity In Clorox?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

• Outshine the giants: these 16 early-stage AI stocks could fund your retirement.
• Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.
• Find 44 companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.